Overview
Bruker Q2 2025 revenue falls 0.4% yoy, missing analyst expectations
Non-GAAP diluted EPS drops 38.5% yoy, missing estimates, per LSEG data
Co announces cost savings initiative to reduce annual costs by $100-120 mln in FY 2026
Outlook
Bruker expects FY 2025 revenue of $3.43 to $3.50 bln
Company anticipates FY 2025 non-GAAP EPS of $1.95 to $2.05
Bruker sees organic revenue decline of 2% to 4% in FY 2025
Company cites US academic market pressure affecting FY 2025 outlook
Result Drivers
DEMAND PRESSURE - Life-science research instruments demand under pressure, particularly in US academic and biopharma markets, per CEO Frank H. Laukien
CURRENCY HEADWINDS - Tariffs and currency headwinds impacted results, despite mitigating actions
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$797.40 mln
$811.40 mln (11 Analysts)
Q2 Adjusted EPS
Miss
$0.32
$0.42 (12 Analysts)
Q2 Net Income
$4.20 mln
Q2 Gross Profit
$357.90 mln
Q2 Operating Expenses
$346 mln
Q2 Operating Income
$11.90 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Bruker Corp is $47.50, about 20% above its August 1 closing price of $37.99
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nBw2PWc6Ba
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)